Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "L04AC" (95)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
What is an ATC-Code?
ATC-Overview
Interleukin Inhibitors (L04AC) 4 products
WHO-DDD
L
IP
CI
Omvoh 100 mg
2
1132.61
1248.20
10 %
Injection solution in prefilled syringe: Mirikizumabum 100 mg/ml
Eli Lilly (Suisse) SA
B / SL
FB
G
IP
CI
Omvoh 100 mg + 200 mg
1 +
k.A.
Injection solution in prefilled syringe: Mirikizumabum 200mg / 2ml
Injection solution in prefilled syringe: Mirikizumabum 100 mg/ml
Eli Lilly (Suisse) SA
B
FB
G
IP
Omvoh 100 mg
2
k.A.
solution injectable en seringue préremplie: Mirikizumabum 100 mg/ml
Eli Lilly (Suisse) SA
B
FB
G
IP
Omvoh 100 mg + 200 mg
1 +
k.A.
solution injectable en seringue préremplie: Mirikizumabum 200mg / 2ml
solution injectable en seringue préremplie: Mirikizumabum 100 mg/ml
Eli Lilly (Suisse) SA
B
FB
G
Basiliximab (L04AC02) 2 products
WHO-DDD
DrugBank.ca
IP
Simulect 20 mg
k.A.
Dry substance: Basiliximabum 20 mg
Novartis Pharma
Schweiz AG
B
FB
G
IP
Simulect 20 mg
ampoule(s)
2050.24
2310.10
k.A.
Pulver und Lösungsmittel zur Herstellung einer Injektions-/Infusionslösung: Basiliximabum 20 mg
Novartis Pharma
Schweiz AG
B
FB
G
Ustekinumab (L04AC05) 29 products
WHO-DDD
DrugBank.ca
L
IP
CI
Stelara 45 mg
3074.64
3360.25
10 %
Injection solution: Ustekinumabum 45mg / 0.5ml
Janssen-Cilag AG
B / SL
FB
G
L
IP
CI
Stelara 45 mg
syringe(s)
3074.64
3360.25
10 %
Injection solution in prefilled syringe: Ustekinumabum 45mg / 0.5ml
Janssen-Cilag AG
B / SL
FB
G
L
IP
CI
Stelara 90 mg
syringe(s)
3074.64
3360.25
10 %
Injection solution in prefilled syringe: Ustekinumabum 90 mg/ml
Janssen-Cilag AG
B / SL
FB
G
L
IP
Stelara 130 mg
3074.64
3360.25
10 %
Concentrate for infusion: Ustekinumabum 130mg / 26ml
Janssen-Cilag AG
B / SL
FB
G
L
IP
CI
Stelara 90 mg/1.0 ml
3074.64
3360.25
10 %
Injektionslösung im Fertigpen: Ustekinumabum 90 mg/ml
Janssen-Cilag AG
B / SL
FB
G
L
IP
CI
Stelara 45 mg/0.5 ml
3074.64
3360.25
10 %
Injektionslösung im Fertigpen: Ustekinumabum 45mg / 0.5ml
Janssen-Cilag AG
B / SL
FB
G
IP
Ustekinumab Spirig HC®
k.A.
Spirig HealthCare AG
FB
G
CM
Streltima 45 mg
k.A.
Injection solution: Ustekinumabum 45mg / 0.5ml
Janssen-Cilag AG
B
FB
G
CM
Streltima 45 mg
k.A.
Injection solution in prefilled syringe: Ustekinumabum 45mg / 0.5ml
Janssen-Cilag AG
B
FB
G
CM
Streltima 90 mg
k.A.
Injection solution in prefilled syringe: Ustekinumabum 90 mg/ml
Janssen-Cilag AG
B
FB
G
IP
CI
Ustekinumab Spirig HC 45 mg / 0.5 ml
k.A.
Injection solution in prefilled syringe: Ustekinumabum 45mg / 0.5ml
Spirig HealthCare AG
B
FB
G
IP
CI
Ustekinumab Spirig HC 90 mg / 1 ml
k.A.
Injection solution in prefilled syringe: Ustekinumabum 90 mg/ml
Spirig HealthCare AG
B
FB
G
CM
Streltima 130 mg
k.A.
Concentrate for infusion: Ustekinumabum 130mg / 26ml
Janssen-Cilag AG
B
FB
G
CM
Streltima 45 mg/0.5 ml
k.A.
Injektionslösung im Fertigpen: Ustekinumabum 45mg / 0.5ml
Janssen-Cilag AG
B
FB
G
CM
Streltima 90 mg/1.0 ml
k.A.
Injektionslösung im Fertigpen: Ustekinumabum 90 mg/ml
Janssen-Cilag AG
B
FB
G
IP
Ustekinumab Spirig HC 130
mg/26 ml
k.A.
Spirig HealthCare AG
B
FB
G
Wezenla 45 mg/0.5 ml
k.A.
Injection solution: Ustekinumabum 45mg / 0.5ml
Amgen Switzerland AG
B
FB
G
Imuldosa 45 mg/0,5 ml
k.A.
Injection solution in prefilled syringe: Ustekinumabum 45mg / 0.5ml
Accord Healthcare AG
B
FB
G
Imuldosa 90 mg/1,0 ml
k.A.
Injection solution in prefilled syringe: Ustekinumabum 90 mg/ml
Accord Healthcare AG
B
FB
G
IP
CI
Pyzchiva 45 mg/0.5 mL
k.A.
Injection solution in prefilled syringe: Ustekinumabum 45mg / 0.5ml
Samsung Bioepis CH
GmbH
B
FB
G
IP
CI
Pyzchiva 90 mg/1 mL
k.A.
Injection solution in prefilled syringe: Ustekinumabum 90 mg/ml
Samsung Bioepis CH
GmbH
B
FB
G
Wezenla 45 mg/0.5 ml
k.A.
Injection solution in prefilled syringe: Ustekinumabum 45mg / 0.5ml
Amgen Switzerland AG
B
FB
G
Wezenla 90 mg/1 ml
k.A.
Injection solution in prefilled syringe: Ustekinumabum 90 mg/ml
Amgen Switzerland AG
B
FB
G
Imuldosa 130 mg / 26 ml
k.A.
Concentrate for infusion: Ustekinumabum 130mg / 26ml
Accord Healthcare AG
B
FB
G
IP
Pyzchiva 130 mg
k.A.
Concentrate for infusion: Ustekinumabum 130mg / 26ml
Samsung Bioepis CH
GmbH
B
FB
G
Steqeyma 130mg / 26mL
k.A.
Concentrate for infusion: Ustekinumabum 130mg / 26ml
iQone Healthcare
Switzerland SA
B
FB
G
Wezenla 130 mg/26 ml
k.A.
Concentrate for infusion: Ustekinumabum 130mg / 26ml
Amgen Switzerland AG
B
FB
G
Steqeyma 45mg / 0.5mL
k.A.
solution injectable en seringue préremplie: Ustekinumabum 45mg / 0.5ml
iQone Healthcare
Switzerland SA
B
FB
G
Steqeyma 90mg / 1.0mL
k.A.
solution injectable en seringue préremplie: Ustekinumabum 90 mg/ml
iQone Healthcare
Switzerland SA
B
FB
G
Tocilizumab (L04AC07) 16 products
WHO-DDD
DrugBank.ca
L
SIP
IP
CI
Actemra 200 mg/10 ml
Durchstechflasche(n)
324.39
369.20
10 %
Concentrate for infusion: Tocilizumabum 200mg / 10ml
Roche Pharma
(Schweiz) AG
A / SL
FB
G
L
SIP
IP
CI
Actemra 400 mg/20 ml
Durchstechflasche(n)
648.78
722.00
10 %
Concentrate for infusion: Tocilizumabum 400mg / 20ml
Roche Pharma
(Schweiz) AG
A / SL
FB
G
L
SIP
IP
CI
Actemra 80 mg/4 ml
Durchstechflasche(n)
129.76
157.55
10 %
Concentrate for infusion: Tocilizumabum 80mg / 4ml
Roche Pharma
(Schweiz) AG
A / SL
FB
G
L
IP
CI
Actemra 162 mg/0.9 ml
4
962.96
1063.70
10 %
Injektionslösung in einem Fertigpen zur subkutanen Anwendung: Tocilizumabum 162mg / 0.9ml
Roche Pharma
(Schweiz) AG
A / SL
FB
G
L
IP
CI
Actemra 162 mg/0.9 ml
4 Fertigspritze(n)
962.96
1063.70
10 %
Injektionslösung zur subkutanen Anwendung: Tocilizumabum 162mg / 0.9ml
Roche Pharma
(Schweiz) AG
A / SL
FB
G
Avtozma 162mg/0.9 ml
4
k.A.
iQone Healthcare
Switzerland SA
A
FB
G
Avtozma 162 mg/0.9 ml
4
k.A.
iQone Healthcare
Switzerland SA
A
FB
G
Avtozma 80 mg/ 4ml
k.A.
Concentrate for infusion: Tocilizumabum 80mg / 10ml
iQone Healthcare
Switzerland SA
A
FB
G
Avtozma 200 mg/10 ml
k.A.
Concentrate for infusion: Tocilizumabum 200mg / 10ml
iQone Healthcare
Switzerland SA
A
FB
G
Avtozma 400 mg/20 ml
k.A.
Concentrate for infusion: Tocilizumabum 400mg / 20ml
iQone Healthcare
Switzerland SA
A
FB
G
Tofidence 80 mg/4 ml
k.A.
Concentrate for infusion: Tocilizumabum 80mg / 4ml
Spirig HealthCare AG
A
FB
G
Tofidence 200 mg/10 ml
k.A.
Concentrate for infusion: Tocilizumabum 200mg / 10ml
Spirig HealthCare AG
A
FB
G
Tofidence 400 mg/20 ml
k.A.
Concentrate for infusion: Tocilizumabum 400mg / 20ml
Spirig HealthCare AG
A
FB
G
Tofidence 80 mg/4 ml
4
k.A.
Concentrate for infusion: Tocilizumabum 80mg / 4ml
Spirig HealthCare AG
A
FB
G
Tofidence 200 mg/10 ml
4
k.A.
Concentrate for infusion: Tocilizumabum 200mg / 10ml
Spirig HealthCare AG
A
FB
G
Tofidence 400 mg/20 ml
4
k.A.
Concentrate for infusion: Tocilizumabum 400mg / 20ml
Spirig HealthCare AG
A
FB
G
Canakinumab (L04AC08) 2 products
WHO-DDD
DrugBank.ca
L
IP
CI
PP
Ilaris
10377.33
10954.95
10 %
Injection solution: Canakinumabum 150 mg/ml
Novartis Pharma
Schweiz AG
A / SL
FB
G
Ilaris 150 mg/ml
k.A.
Injektionslösung in einem Fertigpen: Canakinumabum 150 mg/ml
Novartis Pharma
Schweiz AG
FB
G
Secukinumab (L04AC10) 8 products
WHO-DDD
DrugBank.ca
L
IP
CI
PP
Cosentyx 150 mg / 1 ml
Fertigspritze(n)
538.86
602.45
10 %
Injection solution in prefilled syringe: Secukinumabum 150 mg/ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
PP
Cosentyx 300 mg / 2 ml
1074.57
1185.10
10 %
Injection solution in prefilled syringe: Secukinumabum 300mg / 2ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
PP
Cosentyx 75 mg / 0.5 ml
269.43
309.45
10 %
Injection solution in prefilled syringe: Secukinumabum 75mg / 0.5ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
PP
Cosentyx 150 mg / 1 ml
2 Fertigspritze(n)
1074.57
1185.10
10 %
Injection solution in prefilled syringe: Secukinumabum 150 mg/ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
PP
Cosentyx 150 mg
Durchstechflasche(n)
538.86
602.45
10 %
Dry substance: Secukinumabum 150 mg
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Cosentyx UnoReady 300 mg / 2 ml
1074.57
1185.10
10 %
Injektionslösung im Fertigpen: Secukinumabum 300mg / 2ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
PP
Cosentyx SensoReady 150 mg / 1 ml
538.86
602.45
10 %
Injektionslösung in Fertigpen: Secukinumabum 150 mg/ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
PP
Cosentyx SensoReady 150 mg / 1 ml
2
1074.57
1185.10
10 %
Injektionslösung in Fertigpen: Secukinumabum 150 mg/ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
Siltuximab (L04AC11) 2 products
WHO-DDD
DrugBank.ca
IP
Sylvant 100 mg
Durchstechflasche(n)
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Siltuximabum 110 mg
Medius AG
A
FB
G
IP
Sylvant 400 mg
Durchstechflasche(n)
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Siltuximabum 420 mg
Medius AG
A
FB
G
Ixekizumab (L04AC13) 2 products
WHO-DDD
DrugBank.ca
L
IP
CI
PP
Taltz 80 mg
937.98
1036.55
10 %
Injection solution in prefilled syringe: Ixekizumabum 80 mg
Eli Lilly (Suisse) SA
B / SL
FB
G
L
IP
CI
PP
Taltz 80 mg
937.98
1036.55
10 %
solution injectable en seringue préremplie: Ixekizumabum 80 mg
Eli Lilly (Suisse) SA
B / SL
FB
G
Sarilumab (L04AC14) 4 products
WHO-DDD
L
IP
CI
Kevzara 150 mg/1.14 ml
2
959.37
1059.80
10 %
solution pour injection en seringue préremplie: Sarilumabum 150mg / 1.14ml
Sanofi-Aventis
(Suisse) SA
B / SL
FB
G
L
IP
CI
Kevzara 200 mg/1.14 ml
2
959.37
1059.80
10 %
solution pour injection en seringue préremplie: Sarilumabum 200mg / 1.14ml
Sanofi-Aventis
(Suisse) SA
B / SL
FB
G
L
IP
CI
Kevzara 150 mg/1.14 ml
2
959.37
1059.80
10 %
solution pour injection en stylo prérempli: Sarilumabum 150mg / 1.14ml
Sanofi-Aventis
(Suisse) SA
B / SL
FB
G
L
IP
CI
Kevzara 200 mg/1.14 ml
2
959.37
1059.80
10 %
solution pour injection en stylo prérempli: Sarilumabum 200mg / 1.14ml
Sanofi-Aventis
(Suisse) SA
B / SL
FB
G
Guselkumab (L04AC16) 8 products
WHO-DDD
L
IP
CI
Tremfya 100 mg/1 ml
1906.81
2090.20
10 %
Injection solution in prefilled syringe: Guselkumabum 100 mg/ml
Janssen-Cilag AG
B / SL
FB
G
L
IP
CI
Tremfya 200 mg/2 ml
1906.81
2090.20
10 %
Injection solution in prefilled syringe: Guselkumabum 200mg / 2ml
Janssen-Cilag AG
B / SL
FB
G
L
IP
CI
Tremfya 200 mg/2 ml
2
3813.62
4163.95
10 %
Injection solution in prefilled syringe: Guselkumabum 200mg / 2ml
Janssen-Cilag AG
B / SL
FB
G
L
IP
Tremfya 200 mg/20 ml
3813.62
4163.95
10 %
Concentrate for infusion: Guselkumabum 200mg / 20ml
Janssen-Cilag AG
B / SL
FB
G
L
IP
Tremfya 200 mg/2 ml
1906.81
2090.20
10 %
Injektionslösung im Fertigpen: Guselkumabum 200mg / 2ml
Janssen-Cilag AG
B / SL
FB
G
L
IP
Tremfya 200 mg/2 ml
2
3813.62
4163.95
10 %
Injektionslösung im Fertigpen: Guselkumabum 200mg / 2ml
Janssen-Cilag AG
B / SL
FB
G
L
IP
CI
Tremfya 100 mg/1 ml
1906.81
2090.20
10 %
Injektionslösung in einem Fertigpen: Guselkumabum 100 mg/ml
Janssen-Cilag AG
B / SL
FB
G
IP
CI
Tremfya 100 mg/1 ml
k.A.
Injektionslösung in einem Fertigpen: Guselkumabum 100 mg/ml
Janssen-Cilag AG
B
FB
G
Tildrakizumab (L04AC17) 4 products
WHO-DDD
L
IP
CI
Ilumetri 200 mg/2 ml
2962.66
3238.50
10 %
Injection solution: Tildrakizumabum 200mg / 2ml
Almirall AG
B / SL
FB
G
L
IP
CI
Ilumetri 100 mg/1 ml
2962.66
3238.50
10 %
Injection solution: Tildrakizumabum 100 mg/ml
Almirall AG
B / SL
FB
G
L
IP
CI
Ilumetri, 100 mg/1 ml
2962.66
3238.50
10 %
Injektionslösung im Fertigpen: Tildrakizumabum 100 mg/ml
Almirall AG
B / SL
FB
G
IP
CI
Ilumetri 100 mg/1 ml
2
k.A.
Injection solution: Tildrakizumabum 100 mg/ml
Almirall AG
B
FB
G
Risankizumab (L04AC18) 7 products
WHO-DDD
L
IP
Skyrizi 600 mg/10 ml
2139.56
2343.30
10 %
Concentrate for infusion: Risankizumabum 600mg / 10ml
AbbVie AG
B / SL
FB
G
L
IP
Skyrizi 600 mg/10 ml
2
2139.56
2343.30
10 %
Concentrate for infusion: Risankizumabum 600mg / 10ml
AbbVie AG
B / SL
FB
G
L
IP
CI
Skyrizi 150mg
2877.97
3146.40
10 %
Injektionslösung im Fertigpen: Risankizumabum 150 mg/ml
AbbVie AG
B / SL
FB
G
L
IP
CI
Skyrizi 360 mg
2139.56
2343.30
10 %
Injektionslösung in einer Patrone für ein Dosiergerät: Risankizumabum 360mg / 2.4ml
AbbVie AG
B / SL
FB
G
L
IP
CI
Skyrizi 180 mg
2139.56
2343.30
10 %
Injektionslösung in einer Patrone für ein Dosiergerät: Risankizumabum 180mg / 1.2ml
AbbVie AG
B / SL
FB
G
L
IP
CI
Skyrizi 150 mg
2877.97
3146.40
10 %
lnjektionslösung in einer Fertigspritze: Risankizumabum 150 mg/ml
AbbVie AG
B / SL
FB
G
IP
CI
Skyrizi 75 mg
2
3293.76
3622.10
k.A.
lnjektionslösung in einer Fertigspritze: Risankizumabum 75mg / 0.83ml
AbbVie AG
B
FB
G
Satralizumab (L04AC19) 1 products
WHO-DDD
L
IP
CI
Enspryng 120 mg
6682.56
7164.10
10 %
Injektionslösung zur subkutanen Anwendung: Satralizumabum 120 mg/ml
Roche Pharma
(Schweiz) AG
A / SL
FB
G
Bimekizumab (L04AC21) 6 products
WHO-DDD
L
IP
CI
Bimzelx 160 mg
958.13
1058.45
10 %
Injection solution in prefilled syringe: Bimekizumabum 160 mg/ml
UCB-Pharma SA
B / SL
FB
G
L
IP
CI
Bimzelx 160 mg
2
1916.26
2100.45
10 %
Injection solution in prefilled syringe: Bimekizumabum 160 mg/ml
UCB-Pharma SA
B / SL
FB
G
L
IP
CI
Bimzelx 160 mg
958.13
1058.45
10 %
solution injectable en seringue préremplie: Bimekizumabum 160 mg/ml
UCB-Pharma SA
B / SL
FB
G
L
IP
CI
Bimzelx 160 mg
2
1916.26
2100.45
10 %
solution injectable en seringue préremplie: Bimekizumabum 160 mg/ml
UCB-Pharma SA
B / SL
FB
G
IP
CI
Bimzelx 320 mg
k.A.
Injection solution in prefilled syringe: Bimekizumabum 320mg / 2ml
UCB-Pharma SA
B
FB
G
IP
CI
Bimzelx 320 mg
k.A.
solution injectable en seringue préremplie: Bimekizumabum 320mg / 2ml
UCB-Pharma SA
B
FB
G
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2026
©ywesee GmbH
Settings
|
Help
|
Login
|
Contact
|
Home